🧬 Gene therapy is advancing faster than ever, and the mood at ESGCT and ASHG this year reflected both momentum and maturity. New data revealed fresh confidence in AAV, early breakthroughs in neurological disease, and creative solutions to the cost and scale challenges that

🎙️Tune in to Episode 210 of #TheGeneticsPodcast 🚀 This week on The Genetics Podcast, we’re live from #ASHG2025 with Dr. Heidi Rehm, Chief Genomics Officer at MGH’s Center for Genomic Medicine and Co-director at the Broad Institute, and Dr. Slavé Petrovski, Vice President of

Too often, clinical trial participants are left uninformed about progress, outcomes, or even early termination. In our new report for trial sponsors, we explore: ⚠️ The negative impact of gaps in communication on retention and trust 🚧 Common barriers that make communication so

If you missed last week’s episode of The Genetics Podcast with Chris Hopkins, CEO of Glafabra Therapeutics, we’ve pulled the highlights into a new blog recap. The recap covers: 🧬 How Glafabra’s approach could replace lifelong enzyme infusions with a single, durable treatment 🔁

At ESGCT 2025, one theme stood out: innovation in AAV is shifting from making more to making smarter. Countless talks confirmed that major players are doubling down on AAV gene therapy to push the field even further through: 🧬 Higher yields using better manufacturing 🦠

💡 Rare disease trials often struggle not because of science, but because of human connection. Our rare disease experts have outlined six practical strategies sponsors can use to overcome the most common hurdles, from early patient engagement and flexible design to building

🎙️Tune in to Episode 209 of #TheGeneticsPodcast 🚀 This week, we’re joined by Chris Hopkins, CEO of Glafabra Therapeutics. Listen in to hear about how he and his team are advancing next-generation cell therapy for Fabry disease, exploring the strengths and tradeoffs of different

Participation in clinical trials often demands time, travel, and personal sacrifice from patients. Too often, sponsors fail to communicate results or even acknowledge participants once a study ends. 📉 Only 10% of global clinical trials reviewed included plans to share results

If you missed Patrick’s solo deep dive on The Genetics Podcast last week, we’ve pulled the highlights into a new blog recap. He unpacks the current state of AAV gene therapy, including: 🧬 How AAV therapy works and where it’s delivered the most impact so far ⚠️ The scientific

82% of Phase III trials have at least one protocol amendment. Each one can cost up to $535K and delay timelines. Our new report shares 10 ways sponsors can design trials right the first time. 📖 Download here: https://t.co/mCpSCINeBW #ClinicalTrials #ProtocolAmendments

🎙️ Tune in to Episode 208 of #TheGeneticsPodcast 🚀 This week, Patrick takes a solo deep dive into the current gene therapy landscape. He explores the successes, concerns, and what’s next for AAV delivery, safety, and scalability in rare diseases. 🎧 https://t.co/OuaOf2qjq0 📽️

⏱️ Why does clinical trial start-up still take 4–6 months? Despite huge investments, inefficiencies persist: ⚠️ 11% of sites are never activated ⚠️ Up to 40% of sponsors/CROs are unhappy with start-up In our latest blog, we share best practices to accelerate study start-up and

If you missed our episode with Sonya Dumanis and Andy Singleton last week, we’ve pulled the highlights into a new blog recap. 🌍 Why global representation matters in Parkinson’s genetics 🧬 GP2's blueprint for building local capacity for sustainable scientific discovery 📍 A

If you’ve ever wondered what The Genetics Podcast is all about, our trailer sets the stage for conversations that explore the future of genomics, precision medicine, and rare disease. Over the years, we’ve welcomed incredible guests, including: 💡 Prof Sir Rory Collins (UK

Rare disease trials face unique scientific and logistical hurdles, but success or failure frequently comes down to human connection. In our latest blog, Kendall Davis, Head of Clinical Engagement at Sano Genetics, shares lessons from her extensive experience in rare disease and

At the recent Partnerships with Sites Summit, sessions highlighted just how fast the clinical trial landscape is changing. We covered key takeaways from new data by the Tufts Center for the Study of Drug Development and what it means for sponsors. Key insights from the data: 🔹

🎙️Tune in to Episode 207 of #TheGeneticsPodcast 🚀 This week, we’re joined by Andy Singleton, Program Lead of the Global Parkinson’s Genetics Program (GP2), and Sonya Dumanis, COO of the Coalition for Aligning Science. Listen in to hear about how GP2 was created, their vision

🧡 Advocating for patients is one of the core pillars of our mission at Sano. Clinical trials can be complex and overwhelming, which is why patient support must go beyond logistics. In our latest blog, we take you behind the scenes Cindy Guzman, Patient Navigator Lead, who

🧬 If you missed last week’s episode of The Genetics Podcast with Wanda Smith, founder of CureGRN, we’ve pulled the highlights into a new blog recap. Wanda’s journey began in the 1980s when her mother was misdiagnosed with Alzheimer’s. That experience led her to build a brain

At this year’s DPHARM conference, our VP of Commercial, Ben Jackson, joined a panel with experts from Novartis, BMS, Merck, Tempus, and a leading research site to discuss one of the industry’s toughest challenges: how to match patients to trials effectively while building trust